Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

94
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).

Advances in therapy·2018
Same author

The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?

Primary care diabetes·2018
Same author

Thoughts, Words, Action: The Alma-Ata Declaration to Diabetes Care Transformation.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2018
Same author

Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.

European endocrinology·2018
Same author

Lessons From LEADER - All-round Leadership.

European endocrinology·2018
Same author

Beta-cell Insufficiency.

European endocrinology·2018
Same journal

Predictors of Altmetric Score in Top-Cited Orthopaedic Articles: A Bibliometric Analysis.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Carbon footprint of waste generated in orthopaedic cases in Pakistan: a pilot descriptive study.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Enhancing quotation accuracy assessment with Chatpdf - a game-changer for a century-old conundrum.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Barriers to implementing simulation-based surgical training for improving quality and safety in developing countries: A short communication.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Intraoperative Adverse Event Reporting in Gastrointestinal Cancer Surgery: A Narrative Review on the Application of ClassIntra.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

The Impact of Mortality and Morbidity Meetings on Quality Improvement and Patient Safety.

JPMA. The Journal of the Pakistan Medical Association·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Recent advances in premixed insulin.

Sanjay Kalra

    JPMA. the Journal of the Pakistan Medical Association
    |March 20, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Premixed biphasic insulin is widely used in Pakistan and neighboring regions for diabetes management. This review covers its use in initiating and intensifying treatment, supported by evidence and guidelines, including newer insulin combinations.

    More Related Videos

    An In Ovo Model for Testing Insulin-mimetic Compounds
    06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    11.5K
    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    8.3K

    Related Experiment Videos

    Last Updated: May 2, 2026

    Improving IV Insulin Administration in a Community Hospital
    12:08

    Improving IV Insulin Administration in a Community Hospital

    Published on: June 11, 2012

    19.7K
    An In Ovo Model for Testing Insulin-mimetic Compounds
    06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    11.5K
    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    8.3K

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Premixed biphasic insulin is a common insulin formulation in Pakistan and surrounding countries.
    • It offers a convenient option for managing diabetes mellitus.

    Purpose of the Study:

    • To review the rationale for using premixed insulin in diabetes treatment.
    • To present evidence and guidelines supporting premixed insulin therapy.
    • To discuss recent advancements, including insulin degludec aspart combinations.

    Main Methods:

    • Literature review of studies on premixed insulin.
    • Analysis of clinical guidelines and evidence supporting its use.
    • Discussion of recent developments in insulin formulations.

    Main Results:

    • Premixed insulin is a frequently prescribed option for diabetes management.
    • Evidence supports its efficacy for both initiating and intensifying insulin therapy.
    • Newer formulations like insulin degludec aspart offer advancements.

    Conclusions:

    • Premixed biphasic insulin remains a valuable tool in diabetes care in the region.
    • Guidelines support its use, and ongoing research introduces improved options.
    • Further research into newer combinations is warranted.